Niki BioSolutions, Inc.
NIKI · XNASCIK 1734005fmd_1QC4QJC8QPCAZMRK95ZZCTNX5SManufacturing · Measuring & Controlling Devices, NECTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 17 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 2 | 1 | 0 | – | – |
| Cost of revenue | – | – | – | 1 | 1 | 0 | – | – |
| Realized investment gains (losses) | – | (0) | 25 | (8) | (1) | (0) | (1) | – |
| Gross profit | – | – | – | 0 | 0 | 0 | – | – |
| Operations and maintenance | – | – | – | – | – | 0 | – | – |
| Research and development | 3 | 7 | 12 | 11 | 9 | 5 | 2 | 0 |
| Total operating expenses | 11 | 19 | 21 | 21 | 19 | 0 | – | – |
| Operating income | – | – | – | (21) | (19) | (0) | – | – |
| Interest and investment income | – | – | – | – | 0 | – | – | – |
| Other non-operating income (expense) | (5) | (2) | 25 | (8) | 6 | 6 | (0) | 0 |
| Income before taxes | – | – | – | – | – | (4) | (4) | (1) |
| Net income from continuing operations | – | – | – | – | – | (4) | (4) | (1) |
| Net income | (15) | (20) | 5 | (25) | (10) | (3) | (4) | (1) |
| Net income to common shareholders | – | (19) | 6 | (25) | (10) | (3) | (4) | (1) |